A5100865803- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Immune Cell Function and Interaction
- RNA modifications and cancer
- Immunotherapy and Immune Responses
- Renal cell carcinoma treatment
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Genetic factors in colorectal cancer
- HER2/EGFR in Cancer Research
- PI3K/AKT/mTOR signaling in cancer
- Cancer, Stress, Anesthesia, and Immune Response
- Melanoma and MAPK Pathways
- Estrogen and related hormone effects
- Multiple and Secondary Primary Cancers
- Cutaneous Melanoma Detection and Management
- Nausea and vomiting management
- Cardiac Fibrosis and Remodeling
- Neutropenia and Cancer Infections
Zhejiang Shuren University
2020-2024
Sun Yat-sen University
2020
Sun Yat-sen University Cancer Center
2020
Central South University
2020
Zhejiang University
2010-2018
First Affiliated Hospital Zhejiang University
2010-2018
Shanghai Chest Hospital
2015-2018
Guangdong Academy of Medical Sciences
2018
Guangdong General Hospital
2018
Nanfang Hospital
2015
In this meta-analysis, we analyzed the association between vitamin D levels and lung carcinoma risk outcomes. Two authors independently searched Web of Science, Pubmed, EBSCO Ovid MEDLINE resources with key words "vitamin D, cancer, solar latitude" enrolled 22 studies that satisfied inclusion criteria. The summary odds ratios (ORs) 95% confidence intervals (CIs) were calculated using random (or fixed)-effects model. Potential confounders carefully adjusted. High calcium) intake serum 25(OH)D...
Erythropoietin-producing hepatocellular carcinoma A2 (EphA2) is overexpressed in more than 90% of non-small cell lung cancer (NSCLC) but not significantly normal tissue. It therefore an important tumor antigen target for chimeric receptors (CAR)-T-based therapy NSCLC. Here, we developed a specific CAR targeted to EphA2, and the anti-tumor effects this were investigated. A second generation with co-stimulatory receptor 4-1BB EphA2 was developed. The functionality EphA2-specific T cells vitro...
// Ling Peng 1, * , Yina Wang Yun Hong 2 Xianghua Ye 3 Shi 4, 5 Junyan Zhang 6 and Qiong Zhao 1 Department of Thoracic Oncology, The First Affiliated Hospital, School Medicine, Zhejiang University, Hangzhou, Province, China Pharmacy, Radiotherapy, 4 Medical Statistics, Children's Hospital Fudan Shanghai, Center for Evidence-based Bothwin Clinical Study Consultant, Bellevue, WA, USA These authors contributed equally to this work Correspondence to: Zhao, email: zhaoqiong@zju.edu.cn Keywords:...
Abstract Purpose: Clonal architecture is fundamental for the understanding of cancer biology and therapy; however, multiregional sampling in advanced-stage cancers not always applicable. This prospective clinical trial was to investigate whether paired tissue circulating tumor DNA (ctDNA) could describe clonal advanced non–small cell lung (NSCLC) its association with outcome (NCT03059641). Patients Methods: Paired plasma ctDNA samples were sequenced by target-capture deep sequencing 1,021...
Abstract Introduction Plasma circulating tumor DNA (ctDNA) is an ideal approach to detecting the epidermal growth factor receptor ( EGFR ) T790M mutation, which a major mechanism of resistance first‐generation EGFR‐tyrosine kinase inhibitor (TKI) therapy. The present study aimed explore association ctDNA‐identified mutation with disease failure sites and clinical prognosis in non‐small cell lung cancer (NSCLC) patients. Methods Patients who progressed on TKIs were categorized into site...
Background: rhTPO and rhIL-11 are both recommended for the prophylactic treatment of chemotherapy-induced thrombocytopenia (CIT). However, there has been no head to comparative study on administration alleviate CIT in non-small cell lung cancer (NSCLC). Methods: In this open-label prospective multi-center phase II clinical trial, 108 NSCLC patients who experienced severe after prior chemotherapy were randomized into control arms. Patients arm prophylactically administered day 2, 4, 6 9...
Synchronous multiple primary malignant tumors (MPMTs) are rare in young adults. Genomic profiling of synchronous MPMTs has not been systematically investigated to elucidate their genetic associations, but may be important assist diagnosis and guide appropriate treatment strategy. In the present study, mutation was performed using targeted next generation sequencing (NGS) on 416 cancer-related genes triple lung, kidney thyroid a 32-year-old female patient. The patient diagnosed with...
Diminished or lost Major Histocompatibility Complex class I (MHC-I) expression is frequently observed in tumors, which obstructs the immune recognition of tumor cells by cytotoxic T cells. Restoring MHC-I promoting its transcription and improving protein stability have been promising strategies for reestablishing anti-tumor responses. Here, through cell-based screening models, we found that cediranib significantly upregulated This finding was confirmed various non-small cell lung cancer...